Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Equity Income (2023 - 2025)

Perspective Therapeutics' Equity Income history spans 3 years, with the latest figure at -$1000.0 for Q4 2025.

  • On a quarterly basis, Equity Income rose 50.0% to -$1000.0 in Q4 2025 year-over-year; TTM through Mar 2026 was -$1000.0, a 85.71% increase, with the full-year FY2025 number at -$2000.0, up 75.0% from a year prior.
  • Equity Income hit -$1000.0 in Q4 2025 for Perspective Therapeutics, roughly flat from -$1000.0 in the prior quarter.
  • Over the last five years, Equity Income for CATX hit a ceiling of -$1000.0 in Q1 2025 and a floor of -$12000.0 in Q3 2023.
  • Historically, Equity Income has averaged -$3857.1 across 3 years, with a median of -$2000.0 in 2024.
  • Biggest five-year swings in Equity Income: surged 60.0% in 2024 and later soared 50.0% in 2025.
  • Tracing CATX's Equity Income over 3 years: stood at -$5000.0 in 2023, then surged by 60.0% to -$2000.0 in 2024, then soared by 50.0% to -$1000.0 in 2025.
  • Business Quant data shows Equity Income for CATX at -$1000.0 in Q4 2025, -$1000.0 in Q1 2025, and -$2000.0 in Q4 2024.